NCT04652206 - Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

March 30, 2022

Study Completion Date

May 15, 2022

Conditions

Metastatic Pancreatic AdenocarcinomaLocally Advanced Pancreatic AdenocarcinomaInoperable DiseaseLocalized Pancreatic Adenocarcinoma

Interventions

DRUG

SCO-101

Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.

DRUG

Gemcitabine

Used according to marketing authorisation

DRUG

Nab paclitaxel

Used according to marketing authorisation

Trial Locations (4)

9000

RECRUITING

Aalborg University Hospital, Aalborg

Unknown

RECRUITING

Odense Universitetshospital, Odense

RECRUITING

Catholic Hospital Bochum - St. Josef-Hospital, Bochum

RECRUITING

University Hospital Of Ulm, Ulm